Infusing Renewed Hope into Cancer-related Anemia with Intravenous Iron: AN EXPERT-LED EXPLORATION OF RECENT AND EMERGING TRIAL DATA AND CURRENT GUIDELINE RECOMMENDATIONS
This Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin in a hyperinflammatory disease state like cancer, and the resultant rationale for the preferential use of intravenous (IV) iron versus oral iron modalities in patients with cancer. Finally, the preeminent emphasis of the session will be an incisive exploration of completed, ongoing, and planned clinical trials of IV iron for CRA/CIA, including systematic reviews and meta-analyses, as well as recently-reported pivotal trials, such as IRON-CLAD.
Supported through an independent educational grant from American Regent.
Listen on CEConversations
Hematologists, oncologists, hem/onc residents/fellows, and the interprofessional hematology/oncology care team of nurse practitioners, physician assistants, pharmacists, and nurses.
At the conclusion of this activity, participants will be able to:
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for CRA and CIA evaluating IV iron in combinatorial regimens (i.e., IV iron + ESA) and as monotherapy (i.e., IRON-CLAD, etc.).
- Analyze the safety and efficacy profiles of next-generation IV iron products, with a focus on reduced rates of severe hypersensitivity reactions and unique clinical utility in cancer.
- Apply expert consensus CRA/CIA management guidelines (NCCN, ASCO/ASH, ESMO) to real-world patient cases
George M. Rodgers, MD, PhD
Professor of Medicine
Division of Hematology and Hematologic Malignancies
University of Utah School of Medicine and Huntsman Cancer Center
Salt Lake City, UT
David Henry, MD
Hematology, Medical Oncology
Vice Chair, Department of Medicine
Clinical Professor of Medicine
Abramson Cancer Center
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
George M. Rodgers, MD, PhD–has disclosed that he is an Advisor or Consultant for Pharmacosmos and Sobi.
David Henry, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Patricia Ann Locantore-Ford, MD–has disclosed that she is an Advisor or Consultant for Cardinal Health and Kite.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. All activities will be fully compliant with ACCME Standards for Integrity and Independence in Accredited Continuing Education, as well as AMA, FDA, and PhRMA/OIG guidelines.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation